Renalytix AI expands 'KidneyIntelX' investigator group with three appointments

Kidney disease artificial intelligence diagnostics developer Renalytix AI announced the expansion of its core investigator group for its lead product ‘KidneyIntelX’, for earlier identification of fast-progressing kidney disease in type-2 diabetes on Tuesday.

The AIM-traded firm said the new advisory members were Jonathan Himmelfarb, Joseph Vassalotti and George Bakris.

It said Himmelfarb is a professor at the division of nephrology of the University of Washington, a director at the Kidney Research Institute, a director at the Center for Dialysis Innovation, and a director of the Kidney Precision Medicine Project.

Vassalotti, meanwhile, was the chief medical officer of the National Kidney Foundation, and an associate clinical professor of medicine in the division of nephrology at the Icahn School of Medicine at Mount Sinai.

Finally, Bakris, was a professor of medicine at the University of Chicago, a director at the Comprehensive Hypertension Center, and a member of the board of directors at the National Kidney Foundation.

“The company intends to continue to build a diverse group of leading clinical and research advisors and investigators into its clinical trial, regulatory, reimbursement and commercial adoption programmes for KidneyIntelX,” the Renalytix AI board said in its statement.

“The company believes expert opinion is critical to ensuring quality product development processes that adequately address unmet clinical need in chronic kidney disease and ensure optimal impact on improved patient outcomes and health economics.”

The company also updated the market on the proposed appointment of a new non-executive director, as it announced in its admission document.

Renalytix AI said it intended to be in a position to announce the appointment of a new non-executive director and healthcare industry veteran in advance of its annual general meeting at the end of September.